{"analyses":[{"ciNumSides":"TWO_SIDED","groupDescription":"Mitotic rate correlation with progression-free survival for patients on study treatment.","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Hazard Ratio (HR)","paramValue":"-0.00676","statisticalMethod":"Cox Proportional Hazards","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5","upperLimit":"83","value":"18"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"}],"units":"Participants"}],"description":"Mitotic rate is measured in mitoses per 10 high-power fields","dispersionType":"Full Range","groups":[{"id":"OG000","title":"Women Treated With Adjuvant Regimen for High Risk Uterine LMS"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"2 years","title":"Correlation Between Mitotic Rate and Tumor Response to Treatment (PFS)","type":"SECONDARY","unitOfMeasure":"mitoses per 10 high-power fields"}